ClinicalTrials.gg
CompletedNCT06591598DEUTERONUpdated Nov 3, 2026Results posted

A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

A Phase 4 interventional study of Aflibercept (BAY86-5321, Eylea) in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Bayer. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 4, Interventional, and Other

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
24th of 53
51 · median 49
Started
2024
with 4 others
Phase 4
26 of 53
none open now
Registered
51st of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 24th largest by enrollment, is one of 5 that started in 2024, is one of 26 in phase 4, and was the 51st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).

DME is a diabetes-related eye disorder. In DME, the macula swells up due to fluid leakage from damaged blood vessels, resulting in vision problems. DME is a leading cause of vision loss in working age adults. nAMD is an eye disorder that causes vision loss due to the growth of abnormal blood vessels that leak blood or retinal fluid into the macula (the central part of the retina). nAMD is a leading cause of vision loss for people aged 50 and older.

The study treatment Aflibercept (also called BAY 86-5321) is a drug that blocks a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and leakage of blood vessels at the back of the eye.

The main purpose of this study is to to collect more information on the blood levels of aflibercept when 8 mg aflibercept is injected in both eyes of participants with DME or nAMD.

For this, the researchers will analyze Maximum observed concentration (Cmax): the highest amount of aflibercept in participants' blood will be measured after multiple doses of aflibercept during the study.

Participants will receive 8 mg aflibercept as injections into the vitreous cavity (jelly-like substance that fills the centre of the eye) of both eyes.

Participants will be divided into three groups and will receive initial and maintenance injections of 8 mg aflibercept in both eyes. Researchers will closely monitor the health of the participants during the study.

During the study, the doctors and their study team will:

  • take blood and urine samples
  • do physical examinations
  • examine heart health using electrocardiogram (ECG)
  • check vital signs such as blood pressure, heart rate, body temperature
  • ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

03

Conditions studied

  • Diabetic Macular Edema
  • Neovascular Age-related Macular Degeneration

Browse trials for

Keywords

  • Diabetic macular edema (DME)
  • Neovascular age-related macular degeneration (nAMD)
04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 51 is close to the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥18 years of age (or country's legal age of adulthood if the legal age is >18 years).
  • Participants (treatment naïve or previously treated) requiring intravitreal anti-vascular endothelial growth factor (VEGF) treatment in both eyes in the opinion of the investigator.
  • Participants with type 1 or type 2 diabetes mellitus and DME in both eyes with active central involvement (CI-DME) in at least one eye with central retinal thickness (CRT) ≥300 µm (or ≥320 µm on Spectralis) as determined by the investigator at the screening visit, OR diagnosis of nAMD in both eyes with active subfoveal choroidal neovascularization (CNV) in at least one eye with intraretinal fluid (IRF) and/or subretinal fluid (SRF) on OCT as determined by the investigator at the screening visit.
  • Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320) in eyes with active disease and decreased vision determined to be primarily the result of DME or nAMD.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding. Women of (WOCBP) or men who are sexually active with partners of childbearing potential must agree to use highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last administration of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Evidence of macular edema due to any cause other than diabetes mellitus in patients with DME or neovascular age-related macular degeneration in patients with nAMD in either eye.
  • Active proliferative diabetic retinopathy (DR) in either eye.
  • Panretinal laser photocoagulation (PRP) or macular laser photocoagulation in either eye with CI-DME or active nAMD within 12 weeks (84 days) of the screening visit.
  • Prior treatment with intravitreal (IVT) 2 mg aflibercept (EYLEA) in either eye within 12 weeks (84 days) of the screening visit or with IVT 8 mg or HD aflibercept in either eye within 24 weeks (168 days) of the screening visit.
  • Prior treatment with any other approved IVT agent with anti-VEGF effect (e.g. ranibizumab, bevacizumab, brolucizumab, faricimab, pegaptanib sodium or biosimilars) in either eye within 4 weeks (28 days) of the screening visit.
  • Prior treatment with any ocular gene or cell therapy treatment in either eye.
  • Previous use of intraocular or periocular in either eye within 16 weeks (112 days) of the screening visit, or OZURDEX® implant within 180 days of the screening visit or ILUVIEN® or RETISERT® implant at any time
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Regimen 1

    15 participants will be assigned to Regimen 1. Regimen 1 participants will be administered 8 mg aflibercept injections according to the Regimen 1 dosing schedule.

    Drug: Aflibercept (BAY86-5321, Eylea)

  • Experimental
    Regimen 2

    Up to 15 participants will be assigned to Regimen 2. Regimen 2 participants will be administered 8 mg aflibercept injections according to the Regimen 2 dosing schedule.

    Drug: Aflibercept (BAY86-5321, Eylea)

  • Experimental
    Regimen 3

    Up to 15 participants will be assigned to Regimen 3. Regimen 3 participants will be administered 8 mg aflibercept injections according to the Regimen 3 dosing schedule.

    Drug: Aflibercept (BAY86-5321, Eylea)

Interventions

07

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Free Aflibercept

    Cmax was defined as the maximum observed plasma concentration of free aflibercept for each participant during the regimen-specific semi-dense pharmacokinetic sampling period. Concentrations were assessed at pre-dose and at Days 1, 3, 7, 14, and 28 after the relevant aflibercept administration. The relevant administration was the baseline bilateral administration for Regimen 1, the third same-day bilateral administration at Week 8 for Regimen 2, and the third administration to the second eye for Regimen 3, administered one week after the third administration to the first eye. For each regimen, the highest observed concentration across these sampling points was selected as the participant's Cmax. Participant-level Cmax values were summarized by treatment regimen.

    Time frame: From pre-dose through 28 days after the regimen-specific aflibercept administration used for Cmax determination

08

Results

Posted Nov 3, 2026
Limitations and caveats
The small sample size, together with the known high variability in pharmacokinetic parameters, should be considered when interpreting the study results.

Participant flow

Participant flow — Overall Study
MilestoneRegimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)
Started171915
Completed171714
Not completed021
Withdrew: Lost to follow-up010
Withdrew: Other010
Withdrew: Death001

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of Free Aflibercept

Cmax was defined as the maximum observed plasma concentration of free aflibercept for each participant during the regimen-specific semi-dense pharmacokinetic sampling period. Concentrations were assessed at pre-dose and at Days 1, 3, 7, 14, and 28 after the relevant aflibercept administration. The relevant administration was the baseline bilateral administration for Regimen 1, the third same-day bilateral administration at Week 8 for Regimen 2, and the third administration to the second eye for Regimen 3, administered one week after the third administration to the first eye. For each regimen, the highest observed concentration across these sampling points was selected as the participant's Cmax. Participant-level Cmax values were summarized by treatment regimen.

Time frame:
From pre-dose through 28 days after the regimen-specific aflibercept administration used for Cmax determination
Reported as:
Geometric mean · ug/L
Maximum Observed Concentration (Cmax) of Free Aflibercept
ug/LRegimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)
Maximum Observed Concentration (Cmax) of Free Aflibercept322.09 ± 1.83360.61 ± 1.72466.48 ± 1.54

Adverse events

Collected over Collected from the start of study intervention until the EOS visit, up to 52 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen 1 (Initial Treatment and Maintenance)0/17 (0%)2/17 (11.8%)12/17 (70.6%)
Regimen 2 (Bilateral Simultaneous Treatment)0/19 (0%)2/19 (10.5%)10/19 (52.6%)
Regimen 3 (Bilateral Staggered Treatment)1/15 (6.7%)3/15 (20%)7/15 (46.7%)
Most frequent serious events
Most frequent serious events
EventRegimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)
PneumoniaInfections and infestations0/170/191/15
Pelvic fractureInjury, poisoning and procedural complications0/170/191/15
Cerebrovascular accidentNervous system disorders0/170/191/15
Coronary artery diseaseCardiac disorders1/170/190/15
Pain in extremityMusculoskeletal and connective tissue disorders1/170/190/15
Arteriosclerosis coronary arteryCardiac disorders0/171/190/15
OrchitisInfections and infestations0/171/190/15
Most frequent other events
Showing 10 of 52
Most frequent other events
EventRegimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)
NasopharyngitisInfections and infestations3/170/191/15
COVID-19Infections and infestations2/170/190/15
ConjunctivitisInfections and infestations2/170/190/15
Cataract corticalEye disorders0/172/190/15
Conjunctival haemorrhageEye disorders1/172/190/15
Blood pressure increasedInvestigations1/172/191/15
Intraocular pressure increasedInvestigations0/172/190/15
Posterior capsule opacificationEye disorders0/170/191/15
Vitreous detachmentEye disorders0/170/191/15
Vitreous haemorrhageEye disorders0/170/191/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)Total
Mean64.1 ± 12.867.9 ± 10.168.5 ± 11.366.8 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Regimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)Total
Female681024
Male1111527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White17191551
More than one race0000
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)Total
Hispanic or Latino0000
Not Hispanic or Latino17191551
Unknown or Not Reported0000
nAMD / DME
nAMD / DME(Participants)Regimen 1 (Initial Treatment and Maintenance)Regimen 2 (Bilateral Simultaneous Treatment)Regimen 3 (Bilateral Staggered Treatment)Total
Neovascular age related macular degeneration (nAMD)512421
Diabetic macular edema (DME)1271130
09

Study locations

6 sites
  • Fakultní nemocnice Královské Vinohrady - Urologická klinikay
    Prague, 10034, Czechia
  • Axon Clinical, s.r.o.
    Prague, 150 00, Czechia
  • Budapest Retina Associates
    Budapest, 1133, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Univerzitna nemocnica Bratislava, Nem. Sv. Cyrila a Metoda
    Bratislava, 851 07, Slovakia
  • Fakultna nemocnica s poliklinikou Zilina
    Žilina, 012 07, Slovakia
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Oct 2025, 13 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2024
First posted
Sep 19, 2024
StartActual
Sep 2, 2024
Primary completionActual
Oct 14, 2025
CompletionActual
Oct 14, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMaximum observed concentrationObserved Concentration (Cmax) of free afliberceptFree AfliberceptTime frame: Up to 52 weeks → From pre-dose through 28 days after the regimen-specific aflibercept administration used for Cmax determination
Nov 3, 2026
Documents
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMaximum observed concentrationObserved Concentration (Cmax) of free afliberceptFree AfliberceptTime frame: Up to 52 weeks → From pre-dose through 28 days after the regimen-specific aflibercept administration used for Cmax determination
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT06591598
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 2, 2024
Primary completion
Oct 14, 2025
Completion
Oct 14, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion